• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

PFO-mediated Stroke: Exposing the Misnomer of ‘Cryptogenic’ Stroke
We read with interest the recent article by Wintzer-Wehekind et al1. In an observational study of 453 consecutive patients who underwent PFO closure due to an ischemic event of no other apparent cause, the authors evaluated the safety of discontinuing antithrombotic therapy following PFO closure. At a median follow-up of 8 years, antithrombotic therapy was associated with a 6% incidence of bleeding, and the subset of patients who discontinued their blood thinners did not have more recurrent ischemic events on long-term follow-up.
Source: The American Journal of Cardiology - March 15, 2019 Category: Cardiology Authors: Muhammad O. Zaman, Sanaullah Mojaddedi, Fabian Nietlispach, Bernhard Meier, Mohammad K. Mojadidi Source Type: research

Discriminative Ability of CHA2DS2-VASc and HAS-BLED Score in Whites and Non-Whites
The CHA2DS2-VASc and HAS-BLED scoring systems are used in patients with atrial fibrillation (AF) to estimate risk of stroke and bleeding, respectively. Both were developed in minimally diverse European populations and these scores have not yet been extensively studied in US whites and non-whites. In a retrospective cohort study, we included patients with AF who received inpatient or outpatient care in a large integrated academic health system from 2011 to 2017. Cox proportional hazards were used to analyze associations between stroke and CHA2DS2-VASc score in AF patients not prescribed anticoagulation and between incident ...
Source: The American Journal of Cardiology - March 18, 2019 Category: Cardiology Authors: Sarah M Schwartz, Yacob G Tedla, Philip Greenland, Ajay Yadlapati, Rod Passman Source Type: research

Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism
I read with great interest the paper by Zhang and colleagues1 in which the authors reported that the incidence of stroke and systemic embolism and overall mortality were lower in paroxysmal atrial fibrillation (AF) than in persistent or permanent AF while annualized major bleeding rates were similar across AF types. In truth, this is not a new observation. Ganesan et al.2 reported essentially the same findings in 2016, as have others.3 Importantly, Zhang et al.1 noted that both the CHADS2 and CHA2DS2-VASc risk scoring systems do not consider the type of AF, which may be a significant limitation in their utility if AF type ...
Source: The American Journal of Cardiology - April 8, 2019 Category: Cardiology Authors: James A. Reiffel Tags: Reader's Comments Source Type: research

Discriminative Ability of CHA2DS2-VASc and HAS-BLED Score in Whites and Nonwhites
The CHA2DS2-VASc and HAS-BLED scoring systems are used in patients with atrial fibrillation (AF) to estimate risk of stroke and bleeding, respectively. Both were developed in minimally diverse European populations and these scores have not yet been extensively studied in US whites and nonwhites. In a retrospective cohort study, we included patients with AF who received inpatient or outpatient care in a large integrated academic health system from 2011 to 2017. Cox proportional hazards were used to analyze associations between stroke and CHA2DS2-VASc score in AF patients not prescribed anticoagulation and between incident b...
Source: The American Journal of Cardiology - March 18, 2019 Category: Cardiology Authors: Sarah M. Schwartz, Yacob G. Tedla, Philip Greenland, Ajay Yadlapati, Rod S. Passman Source Type: research

Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism
I read with great interest the paper by Zhang et al1 in which the authors reported that the incidence of stroke and systemic embolism and overall mortality were lower in paroxysmal atrial fibrillation (AF) than in persistent or permanent AF while annualized major bleeding rates were similar across AF types. In truth, this is not a new observation. Ganesan et al2 reported essentially the same findings in 2016, as have others.3 Importantly, Zhang et al1 noted that both the CHADS2 and CHA2DS2-VASc risk scoring systems do not consider the type of AF, which may be a significant limitation in their utility if AF type is truly im...
Source: The American Journal of Cardiology - April 8, 2019 Category: Cardiology Authors: James A. Reiffel Source Type: research

Meta-Analysis Evaluating the Safety and Efficacy of Transcarotid Transcatheter Aortic Valve Implantation
We performed a systemic review and meta-analysis of studies evaluating transcarotid vascular access for transcatheter aortic valve implantation (TAVI). Published studies evaluating transcarotid vascular access for TAVI were included in this analysis. Outcomes of interest included thirty-day mortality, stroke/TIA, new pacemaker implantation, acute kidney injury (AKI), major vascular complication, major bleeding, and myocardial infarction. Pooled estimate for 30-day mortality was 5.3% (95% CI: 4.0%-6.8%; I2=4%), stroke/TIA was 3.4% (95% CI: 2.4%-4.6%; I2=0%), new pacemaker implantation was 15.3% (95% CI: 10.8%-19.7%; I2=72%)...
Source: The American Journal of Cardiology - September 24, 2019 Category: Cardiology Authors: Muhammad Shariq Usman, Wasiq Faraz Rawasia, Tariq Jamal Siddiqi, Firzah Abdul Mujeeb, Shahrukh Nadeem, Mohamad Alkhouli Source Type: research

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by real-world evidence. Systematic review and meta-analysis of observational studies including patients with NVAF on apixaban and rivaroxaban, which reported stroke/systemic embolism and/or major bleeding. Prospero registration number: CRD42021251719. Estimates of relative treatment effect (based on hazard ratios[HRs]) were pooled using the inverse variance method.
Source: The American Journal of Cardiology - December 20, 2021 Category: Cardiology Authors: Mamas A. Mamas, Sarah Batson, Kevin G. Pollock, Sarah Grundy, Andrew Matthew, Chris Chapman, Joana Assis Manuel, Usman Farooqui, Stephen A. Mitchell Source Type: research

Quest for the Perfect Anticoagulant
The current referenced meta-analysis study by Selvaraj et al1 examines the relative merits of anticoagulation with a direct oral anticoagulant (DOAC) versus vitamin K antagonist (VKA) after transcatheter aortic valve implantation (TAVI) in patients meeting the indications for anticoagulation because of atrial fibrillation (AF). Although guidelines vary, the general consensus appears to indicate noninferiority to superiority of DOACs in the treatment of nonvalvular AF. In the landmark Apixiban for Reduction In Stroke and Other Thromboemoblic Events in Atrial Fibrillation trial comparing apixaban to warfarin in patients with...
Source: The American Journal of Cardiology - July 27, 2023 Category: Cardiology Authors: Bryant Fisher, Danny Chu Source Type: research

Renal Impairment in a “Real-Life” Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding)
In conclusion, the presence of impaired renal function was closely related to thrombotic/vascular events, bleeding, and mortality in anticoagulated patients with AF. During follow-up, 1/5 of the patients had significant impairment in renal function. Importantly, normal or mild renal dysfunction at baseline did not exclude the subsequent development of severe renal dysfunction during the follow-up period.
Source: The American Journal of Cardiology - January 21, 2013 Category: Cardiology Authors: Vanessa Roldán, Francisco Marín, Hermógenes Fernández, Sergio Manzano-Fernández, Pilar Gallego, Mariano Valdés, Vicente Vicente, Gregory Y.H. Lip Tags: Arrhythmias and Conduction Disturbances Source Type: research

Safety of Continuous Anticoagulation With Dabigatran During Implantation of Cardiac Rhythm Devices
In conclusion, although no thromboembolic or major bleeding events were observed, additional studies are required to define the optimal antithrombotic management in the perioperative period.
Source: The American Journal of Cardiology - January 28, 2013 Category: Cardiology Authors: Christopher P. Rowley, Michael L. Bernard, William W. Brabham, Peter C. Netzler, Darren S. Sidney, Frank Cuoco, J. Lacy Sturdivant, Robert B. Leman, J. Marcus Wharton, Michael R. Gold Tags: Arrhythmias and Conduction Disturbances Source Type: research

Between a Rock and a Hard Place: Weighing Thrombotic Risk Against Bleeding Complications
The prospect of a further reduction of thrombotic end points (stent thrombosis, acute coronary syndromes, ischemic stroke) may seem appealing and encouraging to clinicians, interventional cardiologists in particular. Be that as it may, are we willing to accept a further reduction in thrombotic events at the trade-off of increasing hemorrhagic risk?
Source: The American Journal of Cardiology - April 25, 2013 Category: Cardiology Authors: Bartosz Hudzik, Lech Polonski Tags: Readers' Comments Source Type: research

Effect of Transcatheter (via Femoral Artery) Aortic Valve Implantation on the Platelet Count and Its Consequences
In conclusion, a decrease in platelet count is a common phenomenon after TAVI, and its severity is associated with poor outcomes.
Source: The American Journal of Cardiology - March 25, 2013 Category: Cardiology Authors: Romain Gallet, Aurelien Seemann, Masanori Yamamoto, Delphine Hayat, Gauthier Mouillet, Jean-Luc Monin, Pascal Gueret, Jean-Paul Couetil, Jean-Luc Dubois-Randé, Emmanuel Teiger, Pascal Lim Tags: Valvular Heart Disease Source Type: research

Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51)
In conclusion, the 2 doses of rivaroxaban reduced cardiovascular events in patients with recent acute coronary syndromes treated with antiplatelet therapies; however, the 2.5-mg dose was associated with lower mortality and fewer bleeding complications than the 5-mg dose. Thus, the addition of rivaroxaban 2.5 mg twice daily offers a more favorable balance of efficacy and safety in patients with recent acute coronary syndromes.
Source: The American Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Sabina A. Murphy, Alexei Plotnikov, Nina Gotcheva, Mikhail Ruda, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research

Thrombocytopenia in Patients With Atrial Fibrillation on Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
In conclusion, mild to moderate baseline thrombocytopenia does not seem to have a clinically significant effect on bleeding or thrombotic or thromboembolic complications after PCI in these frail patients receiving multiple antithrombotic drugs.
Source: The American Journal of Cardiology - May 13, 2013 Category: Cardiology Authors: Tuomas Kiviniemi, Pasi Karjalainen, Andrea Rubboli, Axel Schlitt, Petri Tuomainen, Matti Niemelä, Mika Laine, Fausto Biancari, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research

Applying Antithrombotic Therapies to Improve Outcomes in Patients With Atrial Fibrillation
Abstract: Approximately 15% to 25% or 75,000 ischemic strokes are attributed to atrial fibrillation annually within the United States. Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia and affects more than 2.66 million Americans. Moreover, atrial fibrillation is associated with a 1.5 to 1.9-fold higher risk of death due to its strong correlation with thromboembolic events. Because of the attributed increased morbidity and mortality, challenges that concern identification of patients at risk for thromboembolic events from atrial fibrillation must be addressed. These challenges include compliance to pe...
Source: The American Journal of Cardiology - August 1, 2013 Category: Cardiology Authors: Chris Cannon, Michael D. Ezekowitz, Christopher Granger Tags: Multimedia Activities Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10